The sale will include a $64.4 million term bond due Dec. 1, 2044, and a $134.9 million term bond due Dec. 1, 2054, according to roadshow and offering documents posted Monday on MuniOS. Pricing is ...

"Jake Paul-Mike Tyson fight is the most-bet combat sport (boxing + MMA) in BetMGM history," Alex Rella, senior trader at BetMGM (MGM), told MarketWatch. "Bettors wanted to see Paul get knocked out and ...

The company enjoys strong and relatively stable free cash flow, and this, combined with a fairly modest dividend, creates significant flexibility. Given the change in strategic course, we don't expect ...

The crisis she was focused on - primarily through her popular Instagram account WeBravelyGo, but also on other social-media channels - was climate change, and what realistic things regular people can ...

Here are six topics that are worth bringing up with family members, including parents, kids, and partners. I wrote this article from the perspective of someone with a spouse, retired parents, and ...

MGE has a subsidiary that owns and leases electric generation in the partially owned Elm Road units and the West Campus Cogeneration Facility. The subsidiary is allowed a return on equity above 12% ...

Taxable-bond funds continued their tremendous year, gathering $59 billion of inflows in October. That marked their best month since April 2021 in absolute terms and when scaled for assets. Investors ...

If Kennedy is confirmed, we may lower our US vaccine sales estimates, although we don’t think reductions would be ...

Super Micro Computer Inc. late Monday said it gave Nasdaq a "compliance plan" to support its request for a filing extension in order to keep its listing, and announced a new auditor. Super Micro ...

No, the "Fed model" is not going to sabotage the stock market. I'm referring to the famous market-timing model that compares the stock market's earnings yield (the inverse of the price-to-earnings, or ...

Here are 4 biotech stocks that could get a boost from a more open FDA regulatory climate The key to successful biotech investing is straightforward: Own stocks of companies that get drugs approved.

Asahi is pinning its hopes on premiumization and global expansion to reinvigorate growth. The acquisition of SABMiller’s brands in Europe is a key stepping-stone to establishing its presence in the ...